D. Santoro

Long‐term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis

A. Chuchalin, H. Cicirello, C. Geidel, 2014, Pediatric pulmonology.

Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.

H. Cicirello, M. Govoni, G. Poli, 2013, Pulmonary Pharmacology & Therapeutics.

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers

M. Govoni, D. Santoro, F. Mariotti, 2018, International journal of chronic obstructive pulmonary disease.

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

Dave Singh, C. Francisco, M. Govoni, 2020, Respiratory Research.

A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.

P. Barnes, B. Leaker, D. Singh, 2016, Pulmonary pharmacology & therapeutics.

COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition

H. Watz, Dave Singh, B. Leaker, 2020, European Respiratory Journal.

Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)

K. Beeh, H. Prunier, D. Santoro, 2018, International journal of chronic obstructive pulmonary disease.

The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics

Dave Singh, P. Barnes, B. Leaker, 2014 .

A new eye gel containing sodium hyaluronate and xanthan gum for the management of post-traumatic corneal abrasions

D. Santoro, V. Papa, S. Russo, 2012, Clinical ophthalmology.

Netilmicin/dexamethasone fixed combination in the treatment of conjunctival inflammation

D. Santoro, V. Papa, S. Russo, 2013, Clinical ophthalmology.

Five‐country manikin study found that neonatologists preferred using the LISAcath rather than the Angiocath for less invasive surfactant administration

L. Fabbri, E. Gulczyńska, K. Klebermass-Schrehof, 2018, Acta paediatrica.

A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome.

C. Dani, G. Balla, A. Lavizzari, 2022, The Journal of pediatrics.

Synthetic Surfactant CHF5633 compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double Blind, Randomized, Controlled Clinical Trial.

L. Fabbri, K. Sekar, C. Dammann, 2020, The Journal of pediatrics.

A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome

P. Clarke, L. Fabbri, M. Turner, 2017, Archives of Disease in Childhood: Fetal and Neonatal Edition.

Caffeine Citrate for Apnea of Prematurity: A Prospective, Open-Label, Single-Arm Study in Chinese Neonates

L. Fabbri, Chao Chen, A. Gagnatelli, 2020, Frontiers in Pediatrics.

69 Efficacy on lung function and safety of multiple courses of tobramycin 300mg/4mL nebuliser solution (Bramitob) in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection: results from a 48-week extension phase

H. Cicirello, R. Chiron, H. Mazurek, 2012 .

111 Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection: results in different age subgroups

A. Chuchalin, H. Cicirello, C. Geidel, 2011 .

A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes

P. Clarke, L. Fabbri, M. Turner, 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.